Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
British Journal of Clinical Pharmacology|October 13, 2020
Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjectsYasuhiro Tsuda, Christine Grimaldi, Fenglei Huang, et al.
Pflugers Archiv : European Journal of Physiology|May 3, 2005
Presence of organic anion transporters 3 (OAT3) and 4 (OAT4) in human adrenocortical cellsAbdul R Asif, Jürgen Steffgen, Maria Metten, et al.
European Journal of Clinical Pharmacology|November 12, 2017
Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseasesFredrik N Albach, Frank Wagner, Andreas Hüser, et al.
Lupus|March 19, 2025
Two-year treatment experience with BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: An exploratory, phase II maintenance trialRichard Furie, Jürgen Steffgen, Nora Fagan, et al.
Journal of Clinical Pharmacology|August 17, 2018
Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune DiseasesChristian Schwabe, Bernd Rosenstock, Thi Doan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 11, 2006
Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trialStefan Schreiber, Brian Feagan, Geert D'Haens, et al.
Antimicrobial Agents and Chemotherapy|July 17, 2013
Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis CDominique Larrey, Ansgar W Lohse, Christian Trepo, et al.
British Journal of Clinical Pharmacology|September 28, 2020
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteersTobias Litzenburger, Jürgen Steffgen, Ewald Benediktus, et al.
Antiviral Therapy|March 27, 2009
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatmentAndreas Erhardt, Katja Deterding, Yves Benhamou, et al.
Annals of the Rheumatic Diseases|March 24, 2019
Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa studySudha Visvanathan, Stefan Daniluk, Rafał Ptaszyński, et al.
Pageof 3